Young men and minority patients with early-onset CRC in urban areas face higher CVD death risk, challenging assumptions about ...

Identification of fibroids on ultrasound can prematurely close evaluation, despite frequent co-existence and a ...

Swarup Kumar, MD, discusses how bispecific antibodies are pushing myeloma cure rates to 40%—and what clinicians must know ...

Datopotamab deruxtecan is now a first-line targeted therapy for immunotherapy-ineligible metastatic TNBC, addressing the ~70% lacking actionable PD-L1 eligibility and historically limited to ...

Formal adoption of PMOS replaces a cyst-centric label with terminology capturing endocrine, metabolic, and ovarian ...

Simple FNI labs pinpoint high‑mortality MASLD fibrosis in type 2 diabetes, challenging FIB‑4 and sharpening MASH liver ...

Retatrutide met primary and key secondary endpoints in a 2339-participant, randomized, double-blind, placebo-controlled phase 3 trial, demonstrating clinically meaningful weight reduction across 4, 9, ...

Training deficits in STS brachytherapy stem primarily from limited resident case exposure, despite broad perceived importance ...

Nirogacestat (Ogsiveo; Springworks Therapeutics) is a therapy used to treat desmoid tumors, rare but aggressive growths that ...

Reproductive-care access remains unsettled as mifepristone telehealth/mail distribution is temporarily protected by the ...

The heart failure (HF) treatment landscape continues to evolve rapidly in 2026, with emerging evidence pointing toward a ...

USPSTF recommendations have statutory coverage implications under the ACA, mandating no-cost coverage for graded preventive services and directly shaping access to mammography, colorectal screening, ...